Updated ERAP block/tab info

content/_index.md

@@ -52,7 +52,16 @@ sections:
       title: ERAP
       text: |
         <br>
-        "Evaluating Rapamycin in Alzheimer's disease using Positron emission tomography" (or ERAP for short) is a clinical phase IIa pilot trial. ...     
+        "Evaluating Rapamycin in Alzheimer's disease using Positron emission tomography" (or ERAP for short) is a clinical phase IIa pilot trial. In this one-arm, open-label trial, we assess if the drug rapamycin/sirolimus can be repurposed as a treatment for dementia disorders and neurodegeneration. <br>
+        <br>
+        The trial is a collaboration between Karolinska Institutet and the Karolinska Hospital Memory Clinic in Solna, Sweden. It was initiated on September 1, 2023, and patients with early-stage Alzheimer's disease or mild cognitive impairment are currently being enrolled by invitation. Participants are treated for six months with a weekly dose of 7 mg sirolimus. Before and at the end of the treatment, all participants undergo a series of examinations where we quantify the change in cerebral glucose metabolism, cerebral blood flow, disease-markers in the CSF and cognition. <br>
+        <br>
+        In addition, all participants are examined with a set of medical imaging techniques to quatify change in heart function, bone and muscle density, retinal nerve layer thickness, as well as atherosclerotic- and periodontal inflammation. The purpose of these examinations is to assess if rapamycin affects age-related pathological processes in organs and tissues also outside the central nervous system.  <br>  
+ <br>  
+clinicaltrials.gov ID: NCT06022068 <br>  
+ <br>  
+
+
 
   - block: collection
     id: publications